The ECHELON-1 study compared the experimental brentuximab vedotin plus chemotherapy (A+AVD) to standard ABVD chemotherapy in patients with classical Hodgkin lymphoma. Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses the design and findings of the study as well as what was learned and how this will impact the treatment paradigm.
The abstract entitled ‘First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1’ (Abstract number 7503) was presented at the ASCO annual meeting, June 3-7, 2022.
Questions:
1. Could you give us a brief overview of the ECHELON-1 study and its findings? (0:15)
2. What have we learned from the 6-year follow up data? (1:17)
3. Which patients are likely to benefit most from brentuximab vedotin plus chemotherapy, and in whom is it contraindicated? (2:44)
4. What will be the impact of these findings on the treatment paradigm for Hodgkin lymphoma? (4:38)
Disclosures: Stephen Ansell has received grant/research support from ADC Therapeutics, Affimed, BMS, Pfizer, Regeneron, SeaGen and Takeda and is on the advisory board for Affimed.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
